Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in 2026.

The EMA’s human medicines advisory committee has recommended approval of Eli Lilly’s Baqsimi as the first needle-free treatment for severe low blood sugar levels (hypoglycaemia) in diabetics ...

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of April 2025. The chart below provides highlights of key monograph updates ...

Orforglipron significantly reduced HbA1c levels by 1.3% (3mg), 1.6% (12mg), and 1.5% (36mg) compared with 0.1% in the placebo arm. Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1 ...

The introduction of Primatene Mist ($26.1 million), Baqsimi ($40.4 million), and Albuterol MDI ($40.4 million) was credited by the firm with this growth. Primatene Mist is on track to surpass $100 ...

It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of ...

In a 40-week study, more than 500 people with type 2 diabetes were given either a placebo or one of three possible doses (3mg, 12mg and 36mg) of the drug, orforglipron. Those taking the highest ...

A 12mg dose led to six per cent weight loss over the 10 months, and a 3mg dose five per cent. People taking a fake pill lost 1.6 per cent. The popularity of GLP-1 slimming injections has rocketed ...

The price of the cheapest 2025 MG 3 city hatch has dropped below $22,000 with a new entry-level Vibe model, arriving in showrooms now. And it coincides with the arrival of safety upgrades for the ...